Milestone Pharmaceuticals Inc. - Common Shares - Nakit Akışı (NASDAQ:MIST) | MetaTrader

Tam grafiği aç Full chart

Financials

Genel Bakış Tablolar İstatistikler

Çeyreklik Yıllık

İşletme faaliyetlerinden elde edilen nakit -50.73 M-33.22 M-52.47 M-46.42 M-28.85 M-49.04 M -51.14 M Yatırım faaliyetlerinden elde edilen nakit -70 M70 M-57.12 M4.76 M8.28 M11.25 M -102.37 M Finansman faaliyetlerinden elde edilen nakit 73.22 M5.05 M3.09 M47.79 M32.12 M85.53 M 179.74 M Serbest nakit akışı -50.73 M-33.22 M-52.47 M-46.42 M-28.85 M-49.34 M -51.48 M

Haberler

Milestone Pharmaceuticals Inc. (MIST) Q1 2026 Earnings Call Transcript

Milestone Reports Q1 Results, Highlights Initial CARDAMYST Sales - Milestone Pharmaceuticals (NASDAQ:MIST

Milestone Pharmaceuticals (MIST) Reports Q1 Loss, Lags Revenue Estimates

Milestone Pharmaceuticals kazancı $0,43 ile beklentilere göre daha kötü, kâr ise beklentilere göre düşük

Milestone Pharmaceuticals hisseleri gelir kaybıyla %16 düştü

Milestone Pharmaceuticals gerçek dünya PSVT kayıt çalışması planlıyor

Raymond James, Milestone Pharmaceuticals hissesine Güçlü Al önerisiyle başladı

Milestone Pharmaceuticals Inc. (MIST) Q4 2025 Earnings Call Transcript

Milestone Pharmaceuticals hisse senedi düştü, tahminleri karşıladı

Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Milestone Pharmaceuticals (NASDAQ:MIST)

Milestone Stock: Downgrading To Sell As CARDAMYST Faces A Tough Reality (NASDAQ:MIST)

Milestone Pharmaceuticals appoints David Sandoval as general counsel